Interní Med. 2007; 9(1): 21-27

Angiogenesis in renal cell carcinoma

MUDr. Šárka Lukešová1, MUDr. Otakar Kopecký CSc1, MUDr. Josef Dvořák2, MUDr. Dagmar Hlávková1
1 Ústav klinické imunologie a alergologie, FN a LF UK Hradec Králové
2 Klinika onkologie a radioterapie FN a LF UK Hradec Králové

Angiogenesis represents an essential step in tumour proliferation, expansion, and metastasis. Renal cell carcinoma (RCC) is known to be a well-vascularized tumour. The angiogenic response, also known as the „angiogenic switch“, is initiated when the balance between the positive and the negative regulators of angiogenesis is disrupted in favor of the proangiogenic factors. The role of inactivation of the von Hippel-Lindau tumour suppressor gene in the regulation of proangiogenic factors and the antiangiogenic agents tested in the treatment of RCC is described.

Keywords: Keywords: angiogenesis, renal cell carcinoma, von Hippel-Lindau gene, vascular endothelial growth factor.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukešová Š, Kopecký O, Dvořák J, Hlávková D. Angiogenesis in renal cell carcinoma. Interní Med. 2007;9(1):21-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 2003; 46: S59-S65. Go to original source... Go to PubMed...
    2. Bamias A, Dimopoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Int Med 2003; 14: 459-469. Go to original source... Go to PubMed...
    3. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Research 2002; 62: 4123-4131. Go to PubMed...
    4. Batist G, Champagne P, Hariton C, Dupont E. Dose-survival relationship in a phase II study of neovastat in refractory renal cell carcinoma patients. Proc Am Soc Clin Oncol 2002; 21: A-1907.
    5. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002; 13: 1259-1263. Go to original source... Go to PubMed...
    6. Beecken WD, Bentas W, Glienke W, et al. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma. Eur Urol 2002; 42: 364-369. Go to original source... Go to PubMed...
    7. Bredow S, Lewin M, Hofmann B, et al. Imaging of tumour neovasculature by targeting the TGF? binding receptor endoglin. Eur J Cancer 2000; 36: 675-681. Go to original source... Go to PubMed...
    8. Clifford SC, Astuti D, Hooper L, et al. The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1? in renal cell carcinoma. Oncogene 2001; 20: 5067-5074. Go to original source... Go to PubMed...
    9. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490. Go to original source... Go to PubMed...
    10. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085. Go to original source... Go to PubMed...
    11. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor are we missing the mark? Lancet 2003; 362(9377): 62-64. Go to original source... Go to PubMed...
    12. Deplanque G, Madhusudan S, Jones PH, et al. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer 2004; 91: 1645-1650. Go to original source... Go to PubMed...
    13. Desai AA, Vogelzang NJ, Rini BI, et al. A multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma associated with high rate of venous thromboembolism. Cancer 2002; 95: 1629-1636. Go to original source... Go to PubMed...
    14. Durand RE, Raleigh JA. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res 1998; 58: 3547-3550.
    15. Durand RE, Sham E. The lifetime of hypoxic human tumor cells. Int J Radiat Oncol Biol Phys 1998; 42: 711-715. Go to original source... Go to PubMed...
    16. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380. Go to original source... Go to PubMed...
    17. Eberhard A, Kahlert S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
    18. Eisen T. Phase II results of a phase II/III study comparing thalidomide with medoxyprogesterone in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: 400. Abstract 1606.
    19. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Annals Oncol 2004; 15: 1151-1160. Go to original source... Go to PubMed...
    20. Eleutherakis-Papaiakovou V, Karali M, Kokkonouzis I, Tiliakos I, Dimopoulos MA. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk Lymphoma 2003; 44 (6): 937-948. Go to original source... Go to PubMed...
    21. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Annals Oncol 2002; 13: 1029-1035. Go to original source... Go to PubMed...
    22. Escudier B, Venner P, Stern L, et al. Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: lessons from a large phase III trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (Suppl. 14S): 4547. Go to original source...
    23. Fidler IJ, Kerbel RS, Ellis LM. Biology of cancer angiogenesis, in: DeVita, Hellman, Rosenberg (Eds.), Cancer Principles and Practice of Oncology, sixth ed., Lippincott-Raven, Philadelphia, 2001.
    24. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic platelet-derived endothelial cell growth factor/thymidine phosphorylase is upregulated in breast cancer epithelium and endothelium. Br J Cancer 1996; 73: 275-280. Go to original source... Go to PubMed...
    25. Friesel R, Kamoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689. Go to original source... Go to PubMed...
    26. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22: 385 (abstract 1548).
    27. Gruber M, Simon MC. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol 2006; 13: 169-174. Go to original source... Go to PubMed...
    28. Hagemann T, Gunawan B, Schulz M, et al. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur J Cancer 2001; 37: 1839-1846. Go to original source... Go to PubMed...
    29. Hemmerlein B, Kugler A, Özisik R, et al. Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 2001; 439: 645-652. Go to original source... Go to PubMed...
    30. Hirano Y, Takayama T, Kageyama S, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil. Eur Urol 2003; 43: 45-52. Go to original source... Go to PubMed...
    31. Chang SG, Jeon SH, Lee SJ, et al. Clinical significance of urinary vascular endothelial growth factor and microvessel density in patients with renal cell carcinoma. Urology 2001; 58: 904-908. Go to original source... Go to PubMed...
    32. Igarashi H, Esumi M, Ishida H, Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002; 95: 47-53. Go to original source... Go to PubMed...
    33. Iliopoulos O, Levy AP, Jiang C, et al. negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 2002; 93: 10595-10599. Go to original source... Go to PubMed...
    34. Imazono Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997; 15: 2570-2578. Go to original source... Go to PubMed...
    35. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-557. Go to original source... Go to PubMed...
    36. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU International, 2004; 93: 297-302. Go to original source... Go to PubMed...
    37. Jewell UR, Kvietikova I, Scheid A, et aI. Induction of HIF-I in response to hypoxia is instantaneous. FASEB J 2001; 15: 1312-1314. Go to original source... Go to PubMed...
    38. Kamura T, Maenaka K, Kotoshiba S, et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Develop 2004; 18: 3055-3065. Go to original source... Go to PubMed...
    39. Kedar I, Mermershtain W, Ivgi H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004; 110: 260-265. Go to original source... Go to PubMed...
    40. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19 (Suppl. 18): 45S-51S.
    41. Kerst JM, Bex A, Mallo H, et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005; 54: 926-931. Go to original source... Go to PubMed...
    42. Kim E, Moore J, Huang J, et al. All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms' tumor. J Pediatr Surg 2001; 36: 287-290. Go to original source... Go to PubMed...
    43. Kim W, Kaelin WG. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genetics Develop 2003; 13: 55-60. Go to original source... Go to PubMed...
    44. Kinsui H, Ueda T, Suzuki H, et al. Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res 2002; 93: 340-345. Go to original source... Go to PubMed...
    45. Klener P. Angiogeneze a nádorová onemocnění. Remedia 2002; 12 (1): 2-8.
    46. Klener P. Klinická onkologie. Galén 2002; 66-71.
    47. Klener P. Význam angiogeneze u nádorových onemocnění a možnosti jejího ovlivnění. Forum Medicinae 1999; 2: 54-61.
    48. Krieg M, Haas R, Brauch H, et al. Up-regulation of hypoxia-inducible factors HIF-1? and HIF2? under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435-5443. Go to original source... Go to PubMed...
    49. Kurban G, Hudon V, Duplan E, et al. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 2006; 66 (3): 1313-1319. Go to original source... Go to PubMed...
    50. Lebrin F, Deckers M, Bertolino P, ten Dijke P. TGF-? receptor function in the endothelium. Cardiovasc Res 2005; 65 (3): 599-608. Go to original source... Go to PubMed...
    51. Lein M, Jung K, Laube Ch, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 2000; 85: 801-804. Go to original source... Go to PubMed...
    52. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor by hypoxia. J Biol Chem 1995; 270: 13333-13340. Go to original source... Go to PubMed...
    53. Ljungberg B, Jacobsen J, Häggström-Rudolfssson S, et al. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003; 31: 335-340. Go to original source... Go to PubMed...
    54. Low JA, Johnson MD, Bone EA, et al. The matrix metalloproteinase inhibitor batimastat (BB94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996; 2: 1207-1214.
    55. Malik AK, Gerber HP. Targeting VEGF ligands and receptors in cancer. Targets 2003; 2(2): 48-57. Go to original source...
    56. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
    57. Miller K, Haney L, Pribluda V, et al. A phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol in patients with refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20: 43a (abstract 170). Go to original source...
    58. Miyata Y, Kanda S, Nomata K, et al. Expression of metalloproteinase-2, metalloproteinase9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival. Urol 2004; 63: 602-608. Go to original source... Go to PubMed...
    59. Miyazono K, Okabe T, Urabe A, et al. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987; 262: 4098-4103. Go to original source...
    60. Mizutani Y, Wada H, Yoshida O, et al. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 2003; 98: 730-736. Go to original source... Go to PubMed...
    61. Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia Coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992; 31: 12141-12146. Go to original source... Go to PubMed...
    62. Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20: 302-306. Go to original source... Go to PubMed...
    63. Motzer RJ, Rini BI, Michaelson MD, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22 (Suppl. 14S): 4500. Go to original source... Go to PubMed...
    64. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Seminars Cancer Biol 2004; 14: 123-130. Go to original source... Go to PubMed...
    65. O´Byrne KJ, Dobbs N, Propper D, et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999; 353: 1494-1495. Go to original source... Go to PubMed...
    66. O´Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605. Go to original source... Go to PubMed...
    67. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692. Go to original source... Go to PubMed...
    68. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328. Go to original source... Go to PubMed...
    69. Pal S, Claffey KP, Dvorak HF, Mukhopadhayay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997; 272: 27509-27512. Go to original source... Go to PubMed...
    70. Paradis V, Lagha NB, Zeimoura L, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000; 436: 351-356. Go to original source... Go to PubMed...
    71. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial versus subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98: 4628-4633. Go to original source... Go to PubMed...
    72. Pour L, Hájek R, Buchler T, et al. Angiogeneze a antiangiogenní terapie u nádorů. Vnitř Lék 2004; 50 (12): 930-938. Go to PubMed...
    73. Raia V, Mancuso P, Bertolini F. Antiangiogenesis therapy in the treatment of cancer. Enhancer Biother. Cancer 2005; 3 (1): 2-8.
    74. Ramp U, Reinecke P, Gabbert HE, Gerharz CD. Differential response to transforming growth factor (TGF)-? and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types. Eur J Cancer 2000; 36: 932-941. Go to original source... Go to PubMed...
    75. Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001; 37: 2199-2203. Go to original source... Go to PubMed...
    76. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23 (5): 1028-1043. Go to original source... Go to PubMed...
    77. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 2005; 96: 286-290. Go to original source... Go to PubMed...
    78. Rini BI. VEGF-Targeted therapy in metastatic renal cell carcinoma. Oncologist 2005; 10: 191-197. Go to original source... Go to PubMed...
    79. Ryška A. Angiogeneze v nádorech. Část I.: Úloha v určování biologických vlastností nádoru; faktory ovlivňující vznik a vývoj angiogeneze. Čes-Slov Patol 2000; 36 (1): 26-31. Go to original source...
    80. Salceda S, Cam J. Hypoxia-inducible factor I (HIF-I) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 1997; 272: 22642-22647. Go to original source... Go to PubMed...
    81. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999; 90: 874-879. Go to original source... Go to PubMed...
    82. Shuin T, Yamazaki I, Tamura K, et al. Recent advances in ideas on the molecular pathology and clinical aspects of von Hippel-Lindau disease. Int J Clin Oncol 2004; 9: 283-287. Go to original source... Go to PubMed...
    83. Sin N, Meng L, Wang MQ, et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997; 94: 6099-6103. Go to original source... Go to PubMed...
    84. Singh RK, Gutman M, Bucana CD, et al. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinoma. Proc Natl Acad Sci USA 1995; 92: 4562. Go to original source... Go to PubMed...
    85. Sistla A, Sunga A, Phung K, et al. Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials. Drug Dev Ind Pharm 2004; 30: 19-25. Go to original source... Go to PubMed...
    86. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001; 158 (2): 735-743. Go to original source... Go to PubMed...
    87. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158: 1279-1288. Go to original source... Go to PubMed...
    88. Stadler WM. RMJ: development of target-based anti-neoplastic agents. Invest New Drugs 2000; 18: 7-16. Go to original source... Go to PubMed...
    89. Suzuki K, Morita T, Hashimoto S, Tokue A. Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res 2001; 29: 7-12. Go to original source... Go to PubMed...
    90. Takayashi Y, Bucana CD, Lu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-1151. Go to original source... Go to PubMed...
    91. Takebayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110-1117. Go to original source... Go to PubMed...
    92. Talač R, Žaloudík J, Pačovský Z, Fait V. Neovaskularizace u solidních nádorů. Klin Onkol 1995; 6: 165-167.
    93. Thomas J, Schiller J, Lee F, et al. A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Proc Am Soc Clin Oncol 2001; 20: 70a (abstract 274).
    94. Tomisawa M, Tokunaga T, Oshika Y, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999; 35 (1): 133-137. Go to original source... Go to PubMed...
    95. Tuma RS. Three molecularly targeted drugs tested in kidney cancer clinical trials. J Natl Cancer Inst 2004; 96: 1270-1271. Go to original source... Go to PubMed...
    96. Wada S, Yoshimura R, Naganuma T, et al. Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma. BJU International 2003; 91: 105-108. Go to original source... Go to PubMed...
    97. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor I is a basic-helix -loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-514. Go to original source... Go to PubMed...
    98. Wiesener MS, Münchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1? in clear cell renal carcinomas. Cancer Research 2001; 61: 5215-5222. Go to PubMed...
    99. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189. Go to PubMed...
    100. Yagasaki H, Kawata N, Takimoto Y, Nemoto N. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003; 10: 220-227. Go to original source... Go to PubMed...
    101. Yang JC, Haworth L, Steinberg SM, et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol 2002; 21: 15 (abstract).
    102. Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002; 9: 509-514. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.